Alcon's second quarter revenue of $2.8B and core EPS beat as company raises outlook

Alcon reported strong second quarter results driven by new product launches and robust performance in both Surgical and Vision Care segments. Net sales grew 8% reported (7% cc) to $2.8 billion, while core diluted EPS increased 11% to $0.84. The company raised its full-year 2026 guidance for core operating margin expansion and core EPS growth, reflecting strong operational execution. However, IFRS results were impacted by a $402 million non-cash charge related to the discontinuation of the PowerVision intraocular lens programs.

Key Highlights

• Equipment sales within the Surgical segment surged 26% led by the Unity cataract platform launch.
• Ocular health sales grew 13% constant currency, driven by dry eye brands Tryptyr and Systane.
• Management raised the full-year 2026 core operating margin expansion target to a range of 90 to 190 basis points.